N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide manufacturers
- VU 0255035
-
- $68.00 / 5mg
-
2025-09-11
- CAS:1135243-19-4
- Min. Order:
- Purity: 98.09%
- Supply Ability: 10g
|
| N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide Basic information |
Product Name: | N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide | Synonyms: | N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide;VU 0255035;N-(3-Oxo-3-(4-(pyridin-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonaMide;CID24768606;ML012;N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide hydrate;N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide hydrate;VU0255035 hydrate | CAS: | 1135243-19-4 | MF: | C18H20N6O3S2 | MW: | 432.52 | EINECS: | | Product Categories: | | Mol File: | 1135243-19-4.mol | ![N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide Structure](CAS/GIF/1135243-19-4.gif) |
| N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide Chemical Properties |
Melting point | 159.7-160.2 °C(Solv: dichloromethane (75-09-2); hexane (110-54-3)) | Boiling point | 689.3±65.0 °C(Predicted) | density | 1.447±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO: >5mg/mL | form | powder | pka | 8.97±0.50(Predicted) | color | yellow |
Hazard Codes | Xn | Risk Statements | 22-36/37/38 | Safety Statements | 26 | WGK Germany | 3 |
| N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide Usage And Synthesis |
Uses | VU 0255035 is a novel, selective antagonist of M1 mAChRs, which has potential treatment in CNS disorders. | Definition | ChEBI: N-[3-oxo-3-(4-pyridin-4-yl-1-piperazinyl)propyl]-2,1,3-benzothiadiazole-4-sulfonamide is a member of pyridines and a member of piperazines. | Biological Activity | VU0255035 is the first highly selective antagonist at the orthosteric site of the M1 receptor (75-fold selective for M1 relative to other muscarininc subtypes and devoid of activity at other GPCRs, ion channels, transporters and kinases). There are no highly selective M1 muscarinic receptor antagonists. The existing non-selective drugs do not permit direct evaluation of the role of M1 receptors in CNS fucntions and do not premit therapeutic targeting of M1 receptors in various disease states in which M1 receptors are implicated (epilepsy, Parkinsonμs disease, attention and cognitive disorders, dystonia, etc). | storage | Store at -20°C |
| N-[3-Oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide Preparation Products And Raw materials |
|